FDA expands Casgevy gene therapy to children as young as 2 for sickle cell and beta-thalassemia
FDA clears Vertex’s Casgevy for children aged 2+ with sickle cell disease or transfusion-dependent beta-thalassemia, widening access to a one-time gene therapy.